ARYA Sciences Acquisition Corp. IMTX 深 滬
等待開盤 07-19 09:30:00 美东时间
6.10
-0.110
-1.77%
華盛通- 最 高6.3467
- 今 開6.28
- 成交量 7.97万股
- 最 低 6.10
- 昨 收 6.21
- 總市值 7.44亿
- 52周最高 13.09
- 市盈率 靜 --
- 換手率 0.07%
- 52周最低 3.30
- 委 比 -96.15%
- 總股本 1.22亿
- 歷史最高 18.42
- 量 比 0.49
- 振 幅 3.97%
- 歷史最低 3.30
- 每 手 1
- 風險率 1.29%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to Show Strong Anti-tumor Activity and Durability in Patients with Metastatic Melanoma
Results from the Phase 1b trial of IMA203 PRAME cell therapy in 33 heavily pretreated metastatic melanoma patients show favorable tolerability and durable clinical activity, with a confirmed ORR of 56%, mDOR of 12.1 months, mPFS of 6.1 months, and mOS of 15.9 months. Subgroup analyses demonstrate strong responses in both cutaneous (cORR 50%) and uveal melanoma (cORR 67%). These findings support the ongoing SUPRAME Phase 3 trial and highlight Imma...
05-31 12:00
美股大行评级 | 英伟达、赛富时、C3.ai、Veeva Systems等获多家机构上调目标价！
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1135136987677396993.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• 摩根大通：维持Cogent Biosciences(COGT)"超配"评级，目标价从21美元升至25美元</p> <p>• Chardan Capital：维持Taysha Gene Therapies(TSHA)"买入"
05-30 09:09
美股大行评级 | 拼多多遭多家大行下调评级！Redburn Atlantic首予博通"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1134767544930545665.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Guggenheim：维持AnaptysBio(ANAB)"买入"评级，目标价从54美元升至90美元</p> <p>• Canaccord Genuity：维持Bridger Aerospace Gr(BAER)"买入"评
05-29 09:53
Deutsche Bank Initiates Coverage On Immatics with Buy Rating, Announces Price Target of $10
Deutsche Bank analyst James Shin initiates coverage on Immatics (NASDAQ:IMTX) with a Buy rating and announces Price Target of $10.
05-29 02:29
Immatics GAAP EPS of -€0.33
Immatics press release (NASDAQ:IMTX): Q1 GAAP EPS of -€0.33. Cash and cash equivalents as well as other financial assets of $588.1 million (€543.8 million) as of March 31, 2025; cash reach into 2H 202...
05-13 19:48
Immatics Q1 EPS $(0.35) Misses $(0.33) Estimate, Sales $19.54M Beat $15.42M Estimate
Immatics (NASDAQ:IMTX) reported quarterly losses of $(0.35) per share which missed the analyst consensus estimate of $(0.33) by 6.06 percent. This is a 713.95 percent decrease over losses of $(0.04) per share from the
05-13 19:24
Cantor Fitzgerald Reiterates Overweight on Immaticsto Overweight
Cantor Fitzgerald analyst Eric Schmidt reiterates Immatics (NASDAQ:IMTX) from Overweight to Overweight.
04-01 23:06
Immatics shares are trading higher after the company reported better-than-expected FY24 EPS results.
Immatics shares are trading higher after the company reported better-than-expec...
03-27 23:33
Top-rated biotechs with negative enterprise values
After four consecutive years of underperformance, biotech stocks are among the most unloved segments in the market. Major industry benchmarks SPDR S&P Biotech ETF (NYSEARCA:XBI) and the iShares Biotec...
03-02 03:28
Immatics Advances PRAME Cell Therapy and Expands Oncology Pipeline
Immatics ( ($IMTX) ) has issued an update. Immatics has announced significant a...
01-13 20:55
